March 24, 2020
FDA has announced that it will postpone or cancel all non-essential meetings through April 30, 2020 due to COVID-19. The following meetings are affected:
- April 21, 2020: FDA Pulmonary-Allergy Drugs AdCom to discuss Trelegy Ellipta sNDA for IMPACT trial results (GlaxoSmithKline).
- April 22, 2020: FDA AdCom (undetermined) to discuss sNDA for OCA (Ocaliva) in liver fibrosis due to NASH (Intercept).
- April 23, 2020: FDA imaging Drugs AdCom to discuss NDA for flortaucipir F18, radioactive diagnostic agent for Alzheimer’s disease (Ely Lilly).